Selective pulmonary vasodilator therapy for Persistent Pulmonary Hypertension of the Newborn (PPHN) — інгаляційний оксид азоту при легеневій гіпертензії новонародженого
In utero, the lungs are fluid-filled and pulmonary vascular resistance (PVR) is high — most right ventricular output bypasses the lungs through the ductus arteriosus and foramen ovale. With the first breaths, lung expansion and rising oxygen tension trigger a dramatic fall in PVR, pulmonary blood flow surges, and the fetal shunts begin to close. PPHN occurs when this normal transition fails: PVR remains pathologically elevated, right heart pressure exceeds left heart pressure, and deoxygenated blood continues to shunt right-to-left — producing hypoxemia that is often refractory to supplemental oxygen alone.
Several converging mechanisms keep PVR elevated after birth in PPHN:
• Impaired vasodilation: reduced endothelial nitric oxide synthase (eNOS) activity and lower NO bioavailability blunt the normal postnatal vasodilator surge • Vascular remodeling: chronic intrauterine stress (e.g., placental insufficiency, maternal NSAID/SSRI exposure) can cause abnormal muscularization of small pulmonary arterioles before birth, so the vessels are structurally unable to relax • Lung parenchymal disease: meconium aspiration syndrome, sepsis/pneumonia, and respiratory distress syndrome cause hypoxic pulmonary vasoconstriction and mechanical vessel compression, keeping PVR high secondarily • Lung hypoplasia: congenital diaphragmatic hernia and oligohydramnios-related hypoplasia reduce the cross-sectional area of the pulmonary vascular bed, so resistance stays elevated even with normal vessel tone
Acidosis, hypothermia, and hypoxemia each independently potentiate pulmonary vasoconstriction, creating a vicious cycle: hypoxemia raises PVR, which increases right-to-left shunting, which worsens hypoxemia further.
When right ventricular (and pulmonary artery) pressure exceeds systemic pressure, deoxygenated blood takes the path of least resistance: right-to-left across the patent ductus arteriosus (PDA) and/or the patent foramen ovale (PFO), bypassing the lungs entirely. This produces the clinical hallmark of PPHN — hypoxemia that is disproportionate to the degree of parenchymal lung disease seen on chest imaging, and that responds poorly to increasing inspired oxygen alone because the shunted blood never contacts ventilated alveoli.
A classic bedside clue is a pre-ductal/post-ductal oxygen saturation gradient: saturation measured on the right hand (pre-ductal, before the ductal shunt) that is meaningfully higher (commonly cited as >5–10%) than saturation measured on a lower extremity (post-ductal) suggests ductal right-to-left shunting. Echocardiography confirms the diagnosis: elevated estimated pulmonary artery pressure, right-to-left or bidirectional shunting across the PDA/PFO, and often a flattened or bowing interventricular septum.
Inhaled nitric oxide is delivered as a gas mixed into the ventilator circuit. Because it is inhaled rather than infused intravenously, it reaches pulmonary vascular smooth muscle by diffusing outward from ventilated alveoli — and because it is inactivated the instant it contacts hemoglobin in the bloodstream, its vasodilator effect never reaches the systemic circulation. This anatomic and biochemical selectivity is the central pharmacologic advantage of iNO over intravenous pulmonary vasodilators.
NO gas delivered into the inspired breath travels down the airway to the alveoli, where it dissolves across the thin alveolar-capillary membrane and diffuses directly into the underlying vascular smooth muscle of the adjacent pulmonary arteriole — the vessel that supplies that specific, ventilated alveolar unit. This proximity is what makes the effect anatomically targeted: NO only reaches vessels next to alveoli that are actually receiving gas.
Inside the smooth muscle cell, NO binds the heme moiety of soluble guanylate cyclase (sGC), activating it. Activated sGC converts GTP to cyclic guanosine monophosphate (cGMP). Rising cGMP activates protein kinase G (PKG), which lowers intracellular calcium and desensitizes the contractile apparatus — the smooth muscle relaxes and the vessel dilates, lowering local pulmonary vascular resistance and increasing blood flow through that segment.
cGMP is subsequently broken down by phosphodiesterase-5 (PDE5) — the same enzyme inhibited by sildenafil, which is why sildenafil is sometimes used as an adjunct or bridge during iNO weaning.
The moment NO crosses into the capillary blood itself (rather than staying in the vessel wall), it binds avidly to hemoglobin, forming methemoglobin and nitrate/nitrite byproducts within a fraction of a second. This near-instantaneous inactivation means essentially none of the inhaled NO survives transit through the pulmonary circulation to reach the systemic arterial tree. In contrast, intravenous pulmonary vasodilators (e.g., IV prostacyclin, sildenafil, milrinone) circulate throughout the entire vascular bed and commonly cause systemic hypotension — a major limitation that iNO's local pharmacology avoids.
This is the defining pharmacologic property of inhaled NO: a potent, fast-onset pulmonary vasodilator that is chemically self-limiting to the pulmonary circulation, sparing the newborn from the systemic hypotension that complicates most other vasodilator classes.
A vasodilator delivered intravenously dilates pulmonary vessels indiscriminately — including those supplying poorly ventilated or collapsed lung units — which can worsen ventilation-perfusion (V/Q) mismatch by sending more blood to alveoli that cannot oxygenate it. Because inhaled NO physically only reaches vessels adjacent to ventilated alveoli, it redirects blood flow toward the lung regions best able to oxygenate it, which is why iNO can improve oxygenation more effectively than a systemic vasodilator at an equivalent degree of pulmonary vasodilation.
Effective gas exchange requires ventilation (air reaching alveoli) and perfusion (blood reaching those same alveoli) to be matched. In lung disease, some alveolar units are well-ventilated but under-perfused, while others are poorly ventilated (atelectatic, fluid-filled, or meconium-obstructed) yet still receive blood flow — blood passing through unventilated units returns to the left heart without being oxygenated, functioning as a shunt.
Because inhaled NO cannot reach vessels next to unventilated alveoli (the gas never gets there), it selectively dilates vessels serving ventilated units. This shifts a larger share of total pulmonary blood flow toward alveoli that can actually oxygenate it, improving the efficiency of gas exchange without simply increasing total pulmonary blood flow.
If a non-selective pulmonary vasodilator dilates all pulmonary vessels equally, blood flow to poorly ventilated regions increases along with flow to well-ventilated regions — proportionally, the shunt fraction may not improve, and oxygenation can even worsen despite a fall in mean pulmonary artery pressure. This is a recognized limitation of IV pulmonary vasodilators in patients with heterogeneous lung disease (e.g., meconium aspiration syndrome, where affected and unaffected lung regions are interspersed).
iNO's ventilation-dependent delivery is therefore not just a safety feature (sparing systemic pressure) — it is a mechanistic advantage for oxygenation specifically, particularly when combined with lung-recruitment strategies (optimal PEEP, surfactant, high-frequency ventilation) that maximize the number of alveolar units NO can reach.
iNO therapy is typically initiated near a standard starting dose and its effect is judged empirically against the individual infant's baseline oxygenation — not every infant with PPHN responds to nitric oxide, and response (or lack of it) should actively steer the next clinical decision rather than being treated as a formality.
Randomized trials established that approximately 20 ppm produces near-maximal pulmonary vasodilation for most responders — doses above this range rarely add meaningful further oxygenation benefit and increase the risk of dose-related toxicity (methemoglobinemia, nitrogen dioxide formation from NO reacting with oxygen in the circuit). Clinical protocols therefore typically start at or near the standard dose rather than escalating empirically, and treat higher doses as a deliberate, monitored decision rather than a default titration path.
Response is assessed by comparing oxygenation before and shortly after starting iNO (commonly within 30–60 minutes), using measures such as:
• Change in PaO2 on arterial blood gas at matched FiO2/ventilator settings • Change in the oxygenation index (OI = [mean airway pressure × FiO2 × 100] / PaO2) — a falling OI indicates improved oxygenation efficiency relative to the ventilatory support required • Change in pre-/post-ductal SpO2 and the size of any saturation gradient
A "responder" shows a clinically meaningful improvement in oxygenation attributable to the drug; a "non-responder" shows no meaningful change despite an adequate trial dose and optimized ventilation.
Response classification should directly inform management:
• Responsive: continue iNO at the effective dose, avoid unnecessary escalation, and plan for eventual gradual weaning once the infant is stable • Non-responder at standard dose: reassess reversible contributors first — is ventilation optimized, is there adequate lung recruitment, is there a structural cause (e.g., congenital diaphragmatic hernia, alveolar capillary dysplasia) that iNO cannot fix, is myocardial dysfunction limiting the benefit • Persistent non-response: consider alternative or adjunct therapy (e.g., a PDE5 inhibitor, IV prostacyclin, optimizing sedation/ventilation) and escalation pathways up to ECMO in severe, refractory hypoxemic respiratory failure
Continuing an ineffective dose indefinitely exposes the infant to drug-related risk without benefit, so a defined, timed reassessment is a core part of safe iNO protocols.
Once an infant has stabilized on iNO, the drug cannot simply be switched off. Sustained exposure to exogenous nitric oxide suppresses the infant's own endogenous NO production and increases the enzyme that breaks down cGMP — so abrupt discontinuation removes the vasodilator support the pulmonary vasculature has become dependent on, and can trigger a severe, rapid rebound in pulmonary vascular resistance with life-threatening hypoxemia. Weaning must be slow, stepwise, and closely monitored.
During iNO therapy, two adaptations occur that make the vasculature dependent on the exogenous supply:
• Suppression of endogenous NO production: sustained exogenous NO downregulates the infant's own endothelial nitric oxide synthase (eNOS) activity, reducing native NO generation • Upregulation of phosphodiesterase-5 (PDE5): more of the cGMP-degrading enzyme is expressed, so any given amount of NO/cGMP signal is broken down faster
Together, these mean the vessel wall now relies more heavily on the inhaled NO to maintain the vasodilated state it has settled into — remove that supply suddenly, and there is transiently less vasodilator signal (both endogenous and exogenous) than the vessels had been depending on, so PVR can spike back up sharply.
Rebound after abrupt cessation typically presents within minutes as an acute fall in oxygen saturation, recurrence of a pre-/post-ductal saturation gradient, echocardiographic evidence of rising pulmonary artery pressure and right-to-left shunting, and potential hemodynamic instability from acute right ventricular strain. In a fragile, previously hypoxemic newborn, this can be rapidly life-threatening, which is why abrupt discontinuation — even when the infant appears to be doing well — is considered a preventable safety failure rather than an acceptable shortcut.
Standard practice is a slow, stepwise taper rather than a single stop:
• Confirm clinical stability first: adequate oxygenation on decreasing ventilatory support, no acute illness • Decrease dose in small increments (e.g., halving or stepping down by a few ppm at a time), pausing to reassess oxygenation and vital signs after each step • Slow the pace further as the dose gets low (commonly below ~5 ppm, then down toward ~1 ppm) — the relative risk of rebound is highest at the lowest doses as the vasculature's remaining exogenous support is withdrawn • Only discontinue once the infant tolerates the lowest dose step without any oxygenation deterioration • Have oxygen, ventilatory support, and escalation options readily available throughout the wean in case rebound occurs despite a gradual approach • In select cases, a PDE5 inhibitor (e.g., sildenafil) may be used as a bridging adjunct to help maintain cGMP signaling while iNO is tapered
The operating principle is simple and non-negotiable: taper iNO the way it was started — deliberately, in monitored steps — never abruptly.
The single most important safety rule of inhaled nitric oxide therapy is that it must never be stopped abruptly. Every wean should be gradual, stepwise, and monitored, with resuscitation capability immediately available, because rebound pulmonary hypertension can turn a stable infant critically hypoxemic within minutes.